Divis Laboratories Ltd News

Divi's Labs slips 3% on margin worries; analysts positive on growth outlook

In the March quarter, Divi's Laboratories reported net profit at ₹751 crore, as compared to ₹662 crore a year ago, up 13.4 per cent year-on-year (Y-o-Y)

Nifty, Bank Nifty outlook; Coforge, Divi's Labs among top stock picks

Nifty outlook for today: Option data suggests a broader trading range in between 23,200 to 24,100 zones while an immediate range between 23,400 to 23,900 levels.

Nifty Healthcare below 100-WMA, down 8% from its peak; what charts say?

Amol Athawale of Kotak Securities believes that the short-term outlook for Nifty Healthcare remains uncertain and sentiment may turn negative in case the index falls below 13,500 levels.

Divi's Labs shares fall 3% on Q3 earnings miss; brokerages split on outlook

Divi's Laboratories reported a consolidated profit after tax (PAT) of ₹583 crore, marginally lower than ₹589 crore in the same period last year

Lupin, Biocon: Nifty Pharma gains 3% after US-India trade deal pact

According to Axis Securities, the reduction in reciprocal taxes is incrementally positive for Indian pharmaceutical companies, particularly those with significant exposure to the US market,

Indian CRDMO market to outpace APAC; HDFC Sec starts coverage on top firms

While HDFC Securities has assigned a 'Buy' rating to Divi's Labs, Sai Life Sciences, and Piramal Pharma, it has given an 'Add' rating to Anthem BioSciences and a 'Reduce' rating to Laurus Labs

JB Chem, Divis Labs among top stock recommendations by Vinay Rajani

Vinay Rajani of HDFC Securities says Divis Labs share price has broken out from the box pattern on the daily chart with the primary trend of the stock staying bullish

Pharma index hits 52-week high; Glenmark, Lupin rally 3% in subdued market

In the past two trading days, the Nifty Pharma index has rallied 3.3 per cent, as compared to 0.41 per cent decline in the Nifty 50.